Reyon Pharmaceutical

At a glance

Reyon Pharmaceutical filed 27 disclosures in the last 12 months, including 3 5% holder and 2 issuance. The most recent key filing was on Oct 20: A major holder's stake rose from 0.00% to 5.50%.

Revenue for 2025 was ₩146B, down 1.6% on 2024. It made an operating loss of ₩30.3B. Debt was 111% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩71.9B and operating loss of ₩13.6B.

The 2025 annual report lists 457 employees with an average tenure of 7 years and average pay of ₩76.4M, #458 of 1,829 listed companies by average pay. Its 5 directors and auditors were paid ₩197.1M each on average. It paid no cash dividend for 2025. 유용환 and related parties held 54.37% at year end.

Of 2 recent 5%+ holder reports, 1 raised and 0 cut a stake; the largest stake reported was 53.84% on Oct 8.

From the 2025 annual report

Staff: 457 (309 men, 148 women), of whom 5 on fixed-term contracts. Total pay for the year: ₩34.9B. Directors and auditors: 5, paid ₩985.3M in total.

No cash dividend was paid for 2025.

Largest shareholder

유용환 holds 28.40%; with 4 related parties the group holds 54.37% of common shares at year end (from 55.53% at the start of the year).

Auditor: 삼덕회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary

5%+ holder reports